Physician profile
Debra Fell
NPI 1326025610
$7,232.10
in general payments reported to CMS, 2019-2025
48 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,755 · 2022: $1,778 · 2023: $1,763 · 2024: $915 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,305 · Travel and Lodging: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,304.87 |
| Travel and Lodging | $394.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,264.27 | 2021-2025 | |
| Novo Nordisk INC | $949.16 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $836.03 | 2022-2023 | Intellis Adaptivestim |
| Lilly USA, LLC | $458.64 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $415.75 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $327.18 | 2021-2025 | Verquvo, Belsomra, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.41 | 2021-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $248.76 | 2021-2022 | |
| Amgen INC. | $235.44 | 2021-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $198.22 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $194.91 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.43 | 2021-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $177.34 | 2023-2025 | Rexulti |
| Abbott Laboratories | $127.33 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $117.08 | 2021-2023 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Fell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.